Literature DB >> 31429998

De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.

Jia Li1, Jin Zhang1, Weiting Tang1, Ruth K Mizu1, Hirofumi Kusumoto1, Wenshu XiangWei1, Yuchen Xu1,2, Wenjuan Chen1,2, Johansen B Amin3, Chun Hu1, Varun Kannan1, Stephanie R Keller4, William R Wilcox5, Johannes R Lemke6, Scott J Myers1,7, Sharon A Swanger1, Lonnie P Wollmuth3, Slavé Petrovski8,9, Stephen F Traynelis1,7, Hongjie Yuan1,7.   

Abstract

N-methyl-D-aspartate receptors (NMDARs) mediate slow excitatory postsynaptic transmission in the central nervous system, thereby exerting a critical role in neuronal development and brain function. Rare genetic variants in the GRIN genes encoding NMDAR subunits segregated with neurological disorders. Here, we summarize the clinical presentations for 18 patients harboring 12 de novo missense variants in GRIN1, GRIN2A, and GRIN2B that alter residues in the M2 re-entrant loop, a region that lines the pore and is intolerant to missense variation. These de novo variants were identified in children with a set of neurological and neuropsychiatric conditions. Evaluation of the receptor cell surface expression, pharmacological properties, and biophysical characteristics show that these variants can have modest changes in agonist potency, proton inhibition, and surface expression. However, voltage-dependent magnesium inhibition is significantly reduced in all variants. The NMDARs hosting a single copy of a mutant subunit showed a dominant reduction in magnesium inhibition for some variants. These variant NMDARs also show reduced calcium permeability and single-channel conductance, as well as altered open probability. The data suggest that M2 missense variants increase NMDAR charge transfer in addition to varied and complex influences on NMDAR functional properties, which may underlie the patients' phenotypes.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  GluN; autism; channelopathy; epilepsy; glutamate receptor; intellectual disability; missense variants; movement disorder; neurological diseases; translation study; transmembrane domain

Mesh:

Substances:

Year:  2019        PMID: 31429998      PMCID: PMC6874887          DOI: 10.1002/humu.23895

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  69 in total

Review 1.  NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.

Authors:  Pierre Paoletti; Camilla Bellone; Qiang Zhou
Journal:  Nat Rev Neurosci       Date:  2013-06       Impact factor: 34.870

2.  Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors.

Authors:  Kasper B Hansen; Kevin K Ogden; Hongjie Yuan; Stephen F Traynelis
Journal:  Neuron       Date:  2014-03-05       Impact factor: 17.173

3.  Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats.

Authors:  C Akazawa; R Shigemoto; Y Bessho; S Nakanishi; N Mizuno
Journal:  J Comp Neurol       Date:  1994-09-01       Impact factor: 3.215

Review 4.  Novel drugs and early polypharmacotherapy in status epilepticus.

Authors:  Marta Amengual-Gual; Iván Sánchez Fernández; Mark S Wainwright
Journal:  Seizure       Date:  2018-08-07       Impact factor: 3.184

5.  Epilepsy in patients with GRIN2A alterations: Genetics, neurodevelopment, epileptic phenotype and response to anticonvulsive drugs.

Authors:  C von Stülpnagel; M Ensslen; R S Møller; D K Pal; S Masnada; P Veggiotti; E Piazza; M Dreesmann; T Hartlieb; T Herberhold; E Hughes; M Koch; C Kutzer; K Hoertnagel; J Nitanda; M Pohl; K Rostásy; T B Haack; K Stöhr; G Kluger; I Borggraefe
Journal:  Eur J Paediatr Neurol       Date:  2017-01-14       Impact factor: 3.140

6.  Conserved structural and functional control of N-methyl-D-aspartate receptor gating by transmembrane domain M3.

Authors:  Hongjie Yuan; Kevin Erreger; Shashank M Dravid; Stephen F Traynelis
Journal:  J Biol Chem       Date:  2005-06-21       Impact factor: 5.157

7.  GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects.

Authors:  Konrad Platzer; Hongjie Yuan; Hannah Schütz; Alexander Winschel; Wenjuan Chen; Chun Hu; Hirofumi Kusumoto; Henrike O Heyne; Katherine L Helbig; Sha Tang; Marcia C Willing; Brad T Tinkle; Darius J Adams; Christel Depienne; Boris Keren; Cyril Mignot; Eirik Frengen; Petter Strømme; Saskia Biskup; Dennis Döcker; Tim M Strom; Heather C Mefford; Candace T Myers; Alison M Muir; Amy LaCroix; Lynette Sadleir; Ingrid E Scheffer; Eva Brilstra; Mieke M van Haelst; Jasper J van der Smagt; Levinus A Bok; Rikke S Møller; Uffe B Jensen; John J Millichap; Anne T Berg; Ethan M Goldberg; Isabelle De Bie; Stephanie Fox; Philippe Major; Julie R Jones; Elaine H Zackai; Rami Abou Jamra; Arndt Rolfs; Richard J Leventer; John A Lawson; Tony Roscioli; Floor E Jansen; Emmanuelle Ranza; Christian M Korff; Anna-Elina Lehesjoki; Carolina Courage; Tarja Linnankivi; Douglas R Smith; Christine Stanley; Mark Mintz; Dianalee McKnight; Amy Decker; Wen-Hann Tan; Mark A Tarnopolsky; Lauren I Brady; Markus Wolff; Lutz Dondit; Helio F Pedro; Sarah E Parisotto; Kelly L Jones; Anup D Patel; David N Franz; Rena Vanzo; Elysa Marco; Judith D Ranells; Nataliya Di Donato; William B Dobyns; Bodo Laube; Stephen F Traynelis; Johannes R Lemke
Journal:  J Med Genet       Date:  2017-04-04       Impact factor: 6.318

8.  Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions.

Authors:  Kelly D Farwell; Layla Shahmirzadi; Dima El-Khechen; Zöe Powis; Elizabeth C Chao; Brigette Tippin Davis; Ruth M Baxter; Wenqi Zeng; Cameron Mroske; Melissa C Parra; Stephanie K Gandomi; Ira Lu; Xiang Li; Hong Lu; Hsiao-Mei Lu; David Salvador; David Ruble; Monica Lao; Soren Fischbach; Jennifer Wen; Shela Lee; Aaron Elliott; Charles L M Dunlop; Sha Tang
Journal:  Genet Med       Date:  2014-11-13       Impact factor: 8.822

Review 9.  Human GRIN2B variants in neurodevelopmental disorders.

Authors:  Chun Hu; Wenjuan Chen; Scott J Myers; Hongjie Yuan; Stephen F Traynelis
Journal:  J Pharmacol Sci       Date:  2016-10-19       Impact factor: 3.337

Review 10.  The genetic landscape of the epileptic encephalopathies of infancy and childhood.

Authors:  Amy McTague; Katherine B Howell; J Helen Cross; Manju A Kurian; Ingrid E Scheffer
Journal:  Lancet Neurol       Date:  2015-11-17       Impact factor: 44.182

View more
  23 in total

1.  Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.

Authors:  Weiting Tang; Ding Liu; Stephen F Traynelis; Hongjie Yuan
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

2.  A de novo GRIN1 Variant Associated With Myoclonus and Developmental Delay: From Molecular Mechanism to Rescue Pharmacology.

Authors:  Jin Zhang; Weiting Tang; Nidhi K Bhatia; Yuchen Xu; Nabina Paudyal; Ding Liu; Sukhan Kim; Rui Song; Wenshu XiangWei; Gil Shaulsky; Scott J Myers; William Dobyns; Vasanthi Jayaraman; Stephen F Traynelis; Hongjie Yuan; Xiuhua Bozarth
Journal:  Front Genet       Date:  2021-08-03       Impact factor: 4.599

3.  Synaptic Dysfunction by Mutations in GRIN2B: Influence of Triheteromeric NMDA Receptors on Gain-of-Function and Loss-of-Function Mutant Classification.

Authors:  Marwa Elmasri; James S Lotti; Wajeeha Aziz; Oliver G Steele; Eirini Karachaliou; Kenji Sakimura; Kasper B Hansen; Andrew C Penn
Journal:  Brain Sci       Date:  2022-06-15

Review 4.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

5.  Hodgkin-Huxley-Katz Prize Lecture: Genetic and pharmacological control of glutamate receptor channel through a highly conserved gating motif.

Authors:  Riley E Perszyk; Scott J Myers; Hongjie Yuan; Alasdair J Gibb; Hiro Furukawa; Alexander I Sobolevsky; Stephen F Traynelis
Journal:  J Physiol       Date:  2020-06-15       Impact factor: 5.182

6.  The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca2+ Permeability of GluN1/GluN2A N-Methyl-d-Aspartate Receptors.

Authors:  Riley E Perszyk; Zhaoshi Zheng; Tue G Banke; Jing Zhang; Lingling Xie; Miranda J McDaniel; Brooke M Katzman; Stephen C Pelly; Hongjie Yuan; Dennis C Liotta; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2021-03-09       Impact factor: 4.436

Review 7.  Clinical and therapeutic significance of genetic variation in the GRIN gene family encoding NMDARs.

Authors:  Tim A Benke; Kristen Park; Ilona Krey; Chad R Camp; Rui Song; Amy J Ramsey; Hongjie Yuan; Stephen F Traynelis; Johannes Lemke
Journal:  Neuropharmacology       Date:  2021-09-22       Impact factor: 5.250

Review 8.  Distinct roles of GRIN2A and GRIN2B variants in neurological conditions.

Authors:  Scott J Myers; Hongjie Yuan; Jing-Qiong Kang; Francis Chee Kuan Tan; Stephen F Traynelis; Chian-Ming Low
Journal:  F1000Res       Date:  2019-11-20

Review 9.  From bedside-to-bench: What disease-associated variants are teaching us about the NMDA receptor.

Authors:  Johansen B Amin; Gabrielle R Moody; Lonnie P Wollmuth
Journal:  J Physiol       Date:  2020-04-09       Impact factor: 5.182

10.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.